Regional differences observed in the phase 3 trial (ELM-PC 5) with orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel.

Karim Fizazi, Robert Dreicer, Stéphane Oudard et al.|Journal of Clinical Oncology|2014

Cited by 3